Global mRNA COVID-19 Vaccine 麻豆原创 Growth 2024-2030

Publication ID:

LPI08245762

Publication Date:

August 21, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Messenger ribonucleic acid (mRNA) is a molecule that provides cells with instructions for making proteins. mRNA vaccines contain the instructions for making the SARS-CoV-2 spike protein. This protein is found on the surface of the virus that causes COVID-19. The mRNA molecule is essentially a recipe, telling the cells of the body how to make the spike protein. mRNA COVID-19 Vaccines are given by injection, usually into the muscle of the upper arm.
The global mRNA COVID-19 Vaccine market size is projected to grow from US$ 4138 million in 2023 to US$ 4544.8 million in 2030; it is expected to grow at a CAGR of 1.3% from 2024 to 2030.
The 鈥渕RNA COVID-19 Vaccine Industry Forecast鈥� looks at past sales and reviews total world mRNA COVID-19 Vaccine sales in 2023, providing a comprehensive analysis by region and market sector of projected mRNA COVID-19 Vaccine sales for 2024 through 2030. With mRNA COVID-19 Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA COVID-19 Vaccine industry.
This Insight Report provides a comprehensive analysis of the global mRNA COVID-19 Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA COVID-19 Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global mRNA COVID-19 Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA COVID-19 Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA COVID-19 Vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA COVID-19 Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Non-replicating mRNA Vaccine
Self-amplifying mRNA Vaccine
Segmentation by application
Children
Adults
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Moderna
CanSino Biologicals
Pfizer
Fosun-Pharmaceutical
CSPC Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global mRNA COVID-19 Vaccine market?
What factors are driving mRNA COVID-19 Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do mRNA COVID-19 Vaccine market opportunities vary by end market size?
How does mRNA COVID-19 Vaccine break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global mRNA COVID-19 Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for mRNA COVID-19 Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for mRNA COVID-19 Vaccine by Country/Region, 2019, 2023 & 2030
2.2 mRNA COVID-19 Vaccine Segment by Type
2.2.1 Non-replicating mRNA Vaccine
2.2.2 Self-amplifying mRNA Vaccine
2.3 mRNA COVID-19 Vaccine Sales by Type
2.3.1 Global mRNA COVID-19 Vaccine Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global mRNA COVID-19 Vaccine Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global mRNA COVID-19 Vaccine Sale Price by Type (2019-2024)
2.4 mRNA COVID-19 Vaccine Segment by Application
2.4.1 Children
2.4.2 Adults
2.5 mRNA COVID-19 Vaccine Sales by Application
2.5.1 Global mRNA COVID-19 Vaccine Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global mRNA COVID-19 Vaccine Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global mRNA COVID-19 Vaccine Sale Price by Application (2019-2024)
3 Global mRNA COVID-19 Vaccine by Company
3.1 Global mRNA COVID-19 Vaccine Breakdown Data by Company
3.1.1 Global mRNA COVID-19 Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global mRNA COVID-19 Vaccine Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global mRNA COVID-19 Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global mRNA COVID-19 Vaccine Revenue by Company (2019-2024)
3.2.2 Global mRNA COVID-19 Vaccine Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global mRNA COVID-19 Vaccine Sale Price by Company
3.4 Key Manufacturers mRNA COVID-19 Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers mRNA COVID-19 Vaccine Product Location Distribution
3.4.2 Players mRNA COVID-19 Vaccine Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for mRNA COVID-19 Vaccine by Geographic Region
4.1 World Historic mRNA COVID-19 Vaccine 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global mRNA COVID-19 Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global mRNA COVID-19 Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic mRNA COVID-19 Vaccine 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global mRNA COVID-19 Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global mRNA COVID-19 Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas mRNA COVID-19 Vaccine Sales Growth
4.4 APAC mRNA COVID-19 Vaccine Sales Growth
4.5 Europe mRNA COVID-19 Vaccine Sales Growth
4.6 Middle East & Africa mRNA COVID-19 Vaccine Sales Growth
5 Americas
5.1 Americas mRNA COVID-19 Vaccine Sales by Country
5.1.1 Americas mRNA COVID-19 Vaccine Sales by Country (2019-2024)
5.1.2 Americas mRNA COVID-19 Vaccine Revenue by Country (2019-2024)
5.2 Americas mRNA COVID-19 Vaccine Sales by Type
5.3 Americas mRNA COVID-19 Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA COVID-19 Vaccine Sales by Region
6.1.1 APAC mRNA COVID-19 Vaccine Sales by Region (2019-2024)
6.1.2 APAC mRNA COVID-19 Vaccine Revenue by Region (2019-2024)
6.2 APAC mRNA COVID-19 Vaccine Sales by Type
6.3 APAC mRNA COVID-19 Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe mRNA COVID-19 Vaccine by Country
7.1.1 Europe mRNA COVID-19 Vaccine Sales by Country (2019-2024)
7.1.2 Europe mRNA COVID-19 Vaccine Revenue by Country (2019-2024)
7.2 Europe mRNA COVID-19 Vaccine Sales by Type
7.3 Europe mRNA COVID-19 Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa mRNA COVID-19 Vaccine by Country
8.1.1 Middle East & Africa mRNA COVID-19 Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa mRNA COVID-19 Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa mRNA COVID-19 Vaccine Sales by Type
8.3 Middle East & Africa mRNA COVID-19 Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of mRNA COVID-19 Vaccine
10.3 Manufacturing Process Analysis of mRNA COVID-19 Vaccine
10.4 Industry Chain Structure of mRNA COVID-19 Vaccine
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 mRNA COVID-19 Vaccine Distributors
11.3 mRNA COVID-19 Vaccine Customer
12 World Forecast Review for mRNA COVID-19 Vaccine by Geographic Region
12.1 Global mRNA COVID-19 Vaccine 麻豆原创 Size Forecast by Region
12.1.1 Global mRNA COVID-19 Vaccine Forecast by Region (2025-2030)
12.1.2 Global mRNA COVID-19 Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global mRNA COVID-19 Vaccine Forecast by Type
12.7 Global mRNA COVID-19 Vaccine Forecast by Application
13 Key Players Analysis
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna mRNA COVID-19 Vaccine Product Portfolios and Specifications
13.1.3 Moderna mRNA COVID-19 Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 CanSino Biologicals
13.2.1 CanSino Biologicals Company Information
13.2.2 CanSino Biologicals mRNA COVID-19 Vaccine Product Portfolios and Specifications
13.2.3 CanSino Biologicals mRNA COVID-19 Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 CanSino Biologicals Main Business Overview
13.2.5 CanSino Biologicals Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer mRNA COVID-19 Vaccine Product Portfolios and Specifications
13.3.3 Pfizer mRNA COVID-19 Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Fosun-Pharmaceutical
13.4.1 Fosun-Pharmaceutical Company Information
13.4.2 Fosun-Pharmaceutical mRNA COVID-19 Vaccine Product Portfolios and Specifications
13.4.3 Fosun-Pharmaceutical mRNA COVID-19 Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Fosun-Pharmaceutical Main Business Overview
13.4.5 Fosun-Pharmaceutical Latest Developments
13.5 CSPC Pharmaceutical
13.5.1 CSPC Pharmaceutical Company Information
13.5.2 CSPC Pharmaceutical mRNA COVID-19 Vaccine Product Portfolios and Specifications
13.5.3 CSPC Pharmaceutical mRNA COVID-19 Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 CSPC Pharmaceutical Main Business Overview
13.5.5 CSPC Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.